Internal Medicine
Adrenal failure: an evidence-based diagnostic approach
6 Jun, 2023 | 14:16h | UTCAdrenal Failure: An Evidence-Based Diagnostic Approach – Diagnostics
RCT | Noninferiority shown between DOACs and LMWH for recurrent VTE prevention in cancer patients
5 Jun, 2023 | 13:50h | UTCSummary: This unblinded, pragmatic, noninferiority randomized clinical trial aimed to assess the efficacy of direct oral anticoagulants (DOACs) against low-molecular-weight heparin (LMWH) in preventing recurrent venous thromboembolism (VTE) in patients with cancer. The study included 671 patients from 67 oncology centers, with a new clinical or radiological diagnosis of VTE.
Participants were randomly assigned to receive either a DOAC or LMWH for 6 months, and treating physicians selected and prescribed the drugs based on considerations like availability and drug-drug interactions. The primary outcome was the rate of recurrent VTE at 6 months. Findings revealed that the DOAC group had a recurrent VTE rate of 6.1% as compared to 8.8% in the LMWH group, showing noninferiority. Both groups had statistically similar rates of major bleeding and severe adverse events.
This pragmatic study included patients with advanced cancer and brain metastases, impaired performance status, and reduced liver or kidney function, making it more representative of routine oncology practice. Moreover, patient adherence to DOAC treatment was significantly higher than to LMWH. Nevertheless, the study had limitations, including the lack of blinding and underrepresentation of certain racial and ethnic groups.
In conclusion, this trial suggests that DOACs were noninferior to LMWH for preventing recurrent VTE in patients with cancer over a 6-month follow-up period, supporting the use of DOACs in this population for VTE prevention. Further research is needed to confirm these results and investigate long-term outcomes.
Article: Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients With Cancer: A Randomized Clinical Trial – JAMA (free for a limited period)
See also: Visual abstract
Commentary on Twitter
Among adults with cancer and VTE, direct oral anticoagulants were noninferior to low-molecular-weight heparin for preventing recurrent VTE over 6-month follow-up. #ASCO23 https://t.co/DP5RvlSYxe pic.twitter.com/rBJ99plopK
— JAMA (@JAMA_current) June 2, 2023
Review | Prevention of venous thromboembolism in patients with cancer
5 Jun, 2023 | 13:48h | UTCPrevention of venous thromboembolism in patients with cancer – The BMJ
ESAIC focused guideline for the use of cardiac biomarkers in perioperative risk evaluation
5 Jun, 2023 | 13:37h | UTC
RCT | Sulbactam-durlobactam non-inferior to colistin for acinetobacter baumannii-calcoaceticus complex infections
5 Jun, 2023 | 13:31h | UTCEfficacy and safety of sulbactam–durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii–calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK) – The Lancet Infectious Diseases (link to abstract – $ for full-text)
News Release: Novel Antibiotic Succeeds in Trial Against Hospital-Acquired Pneumonia – Rutgers University
Cohort Study | Cannabis use disorder linked to increased risk of depression and bipolar disorder
5 Jun, 2023 | 13:26h | UTCCannabis Use Disorder and Subsequent Risk of Psychotic and Nonpsychotic Unipolar Depression and Bipolar Disorder – JAMA Psychiatry (link to abstract – $ for full-text)
Author Interview: Cannabis Use Disorder and Subsequent Risk of Unipolar Depression and Bipolar Disorder
Commentary: Expert reaction to study of cannabis use disorder, bipolar disorder, and depression – Science Media Centre
Review | Hypovolemia with peripheral edema: what is wrong?
5 Jun, 2023 | 13:18h | UTCHypovolemia with peripheral edema: What is wrong? – Critical Care
M-A | Efficacy and safety of duloxetine in chronic musculoskeletal pain
5 Jun, 2023 | 13:09h | UTC
Global, regional, and national burden of low back pain, 1990–2020, its attributable risk factors, and projections to 2050
2 Jun, 2023 | 12:34h | UTCEditorial: The global epidemic of low back pain – The Lancet Rheumatology
News Releases:
Commentary on Twitter
NEW—GBD 2021 data published in @TheLancetRheum finds low back pain is the leading cause of disability globally. #LowBackPain affects 619 million individuals (1 out of every 13 people). More women across all age groups suffered from low back pain than men.https://t.co/A2RoU9hn9p pic.twitter.com/vhXwcVh1e7
— Institute for Health Metrics and Evaluation (IHME) (@IHME_UW) May 22, 2023
ACR Guideline for exercise, rehabilitation, diet, and additional integrative interventions for rheumatoid arthritis
2 Jun, 2023 | 12:33h | UTCNews Release: New Guideline Introduces Recommendations for Integrative Approach to RA Treatment – American College of Rheumatology
M-A | Coronary revascularization in HF and CAD: a small but significant effect on mortality
2 Jun, 2023 | 12:31h | UTC
Systematic Review | Bupropion and nortriptyline: an assessment of their effectiveness in smoking cessation
2 Jun, 2023 | 12:28h | UTCAntidepressants for smoking cessation – Cochrane Library
Consensus Document | Diagnosis and treatment of lupus nephritis
2 Jun, 2023 | 12:26h | UTC
M-A | Residual respiratory disability after successful treatment of pulmonary tuberculosis
2 Jun, 2023 | 12:20h | UTC
Juvenile idiopathic inflammatory myositis: an update on pathophysiology and clinical care
2 Jun, 2023 | 12:18h | UTC
Review | Interventional therapies for pulmonary embolism
2 Jun, 2023 | 12:16h | UTCInterventional therapies for pulmonary embolism – Nature Reviews Cardiology (if the link is paywalled, try this one)
Commentary on Twitter
In our latest Review, @FelixMahfoud et al. discuss interventional therapies for pulmonary embolism. Check it out here: https://t.co/sBDfnZno1q pic.twitter.com/XNLclSbjmr
— Nature Reviews Cardiology (@NatRevCardiol) May 14, 2023
Review | Subclinical hypothyroidism: let the evidence be your guide
2 Jun, 2023 | 12:08h | UTCSubclinical hypothyroidism: Let the evidence be your guide – Journal of Family Practice
Review | Medication-assisted recovery for opioid use disorder
2 Jun, 2023 | 12:03h | UTCMedication-assisted recovery for opioid use disorder: A guide – Journal of Family Practice
Review | These USPSTF recommendations should be on your radar
2 Jun, 2023 | 11:59h | UTCThese USPSTF recommendations should be on your radar – Journal of Family Practice
ASH 2023 Guidelines for management of venous thromboembolism | Thrombophilia testing
1 Jun, 2023 | 12:22h | UTC
AASLD-IDSA Guideline | Updated 2023 recommendations for the testing, management, and treatment of Hepatitis C virus infection
1 Jun, 2023 | 12:21h | UTC
RCT | Dupilumab improves lung function and reduces exacerbations in COPD patients with elevated eosinophils
1 Jun, 2023 | 12:20h | UTCDupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Dupilumab Improves Outcomes for COPD, Type 2 Inflammation in Randomized Trial – HCP Live
Commentary on Twitter
Presented at #ATS2023: In the BOREAS trial, dupilumab resulted in a lower annualized rate of exacerbations than placebo among patients with COPD and an elevated blood eosinophil count. Full trial results: https://t.co/9IWZr3YqsN
— NEJM (@NEJM) May 21, 2023
Phase 2b RCT | Danuglipron, an oral GLP-1R agonist, reduces body weight and improves glycemic control in type 2 diabetes
1 Jun, 2023 | 12:17h | UTC
SR | Systematic review finds 16.4-36.18 severe bleedings, 7.62-8.5 perforations per 10,000 colonoscopies
1 Jun, 2023 | 12:15h | UTC
Expert Consensus | Nephrotoxic potential of 195 medications in the non-intensive care setting
1 Jun, 2023 | 12:14h | UTC